Mseek: a technique for ultra-pure mitochondrial DNA sequencing
Researchers at the Icahn School of Medicine at Mount Sinai have developed Mseek, a technique that enzymatically deletes nuclear DNA to leave highly pure mitochondrial DNA for deep sequencing. The method achieves unprecedented sensitivity and specificity for detecting mtDNA variants — including low-level heteroplasmy — confirmed stable at single-cell level across cell divisions. If it translates, mtDNA could become a usable biomarker and therapeutic target in cancer and inherited disease, according to coverage September 25, 2026.
How does Mseek work?
By chewing away the nuclear genome enzymatically and leaving mitochondrial DNA intact, the technique produces an exceptionally clean mtDNA sample — so sequencing reads land on the mitochondrial genome instead of being drowned out by nuclear DNA, including the nuclear copies of mitochondrial sequences that confound ordinary mtDNA analysis.
Why is pure mtDNA hard to sequence?
Human cells carry thousands of mitochondrial genomes alongside two copies of the nuclear genome, and the nucleus contains ancient mitochondrial insertions (NUMTs) that masquerade as real mtDNA variants. Low-level heteroplasmy — a small fraction of mutated copies — is easy to miss and hard to interpret. Purity is the prerequisite for precision.
How does this connect to mitochondrial testing?
Validated mitochondrial testing depends on reliably detecting the variants that matter. A technique that makes heteroplasmy measurable at single-cell resolution could sharpen both clinical diagnostics for inherited mitochondrial disease and research into mtDNA's role in cancer and aging.
Where does the evidence stand?
Cell-line validation is strong; clinical utility is not yet demonstrated. Mseek is an enabling technique, not a test you can order — but it is the kind of enabling technique that new tests get built on.
Where the evidence stands
- Established: The technique's sensitivity and specificity for mtDNA variant detection were validated in cell-line experiments, with stability across cell divisions.
- Preliminary: Whether Mseek improves clinical diagnostics or enables mtDNA-based biomarkers in cancer or inherited disease has not been demonstrated.
- Absent: No clinical test based on Mseek is available.